Steven Fletcher

List of Publications by Year
in descending order

57	1,696	304743 22	289244 40
papers	citations	h-index	g-index

58	58	58	2619
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Targeting proteinâ€“protein interactions by rational design: mimicry of protein surfaces. Journal of the Royal Society Interface, 2006, 3, 215-233.	3.4	151
2	Small-molecule inhibitors of the Myc oncoprotein. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2015, 1849, 525-543.	1.9	127
3	Inhibition of TLR2 signaling by small molecule inhibitors targeting a pocket within the TLR2 TIR domain. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 5455-5460.	7.1	124
4	Protein surface recognition and proteomimetics: mimics of protein surface structure and function. Current Opinion in Chemical Biology, 2005, 9, 632-638.	6.1	122
5	Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules. Journal of Medicinal Chemistry, 2017, 60, 821-838.	6.4	81
6	The novel BH3 Î±-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon) Tj ETQq0 0 0 rgBT /Overlock 1 Molecular Cancer, 2013, 12, 42.	19.2	78
7	Perturbation of the c-Mycâ€“Max Proteinâ€“Protein Interaction via Synthetic Î±-Helix Mimetics. Journal of Medicinal Chemistry, 2015, 58, 3002-3024.	6.4	76
8	BRD4 Structureâ€“Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536. ACS Medicinal Chemistry Letters, 2015, 6, 764-769.	2.8	74
9	Protein-Protein Interaction Inhibitors: Small Molecules from Screening Techniques. Current Topics in Medicinal Chemistry, 2007, 7, 922-927.	2.1	71
10	MCL-1 inhibitors â€“ where are we now (2019)?. Expert Opinion on Therapeutic Patents, 2019, 29, 909-919.	5.0	50
11	Concise access to N9-mono-, N2-mono- and N2,N9-di-substituted guanines via efficient Mitsunobu reactions. Tetrahedron, 2010, 66, 4621-4632.	1.9	49
12	Structure-based design of N-substituted 1-hydroxy-4-sulfamoyl-2-naphthoates as selective inhibitors of the Mcl-1 oncoprotein. European Journal of Medicinal Chemistry, 2016, 113, 273-292.	5.5	42
13	Amphipathic Î±-Helix Mimetics Based on a 1,2-Diphenylacetylene Scaffold. Organic Letters, 2013, 15, 3234-3237.	4.6	41
14	Structure-Based Design and Synthesis of Potent, Ethylenediamine-Based, Mammalian Farnesyltransferase Inhibitors as Anticancer Agents. Journal of Medicinal Chemistry, 2010, 53, 6867-6888.	6.4	38
15	Mcl-1 inhibitors: a patent review. Expert Opinion on Therapeutic Patents, 2017, 27, 163-178.	5.0	36
16	Discovery of Methyl 4â€²â€Methylâ€5â€(7â€nitrobenzo[c][1,2,5]oxadiazolâ€4â€yl)â€[1,1â€²â€biphenyl]â€3â€carboxylate, an Improved Smallâ€Molecule Inhibitor of câ€Mycâ€“Max Dimerization. ChemMedChem, 2014, 9, 2274-2285.	3.2	35
17	Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRaf. Biochemical Journal, 2015, 467, 425-438.	3.7	35
18	Potent, Plasmodium-Selective Farnesyltransferase Inhibitors That Arrest the Growth of Malaria Parasites: Structureâ^'Activity Relationships of Ethylenediamine-Analogue Scaffolds and Homology Model Validation. Journal of Medicinal Chemistry, 2008, 51, 5176-5197.	6.4	33

#	Article	IF	Citations
19	Facile and efficient access to 2,6,9-tri-substituted purines through sequential N9, N2 Mitsunobu reactions. Tetrahedron Letters, 2009, 50, 4258-4261.	1.4	29
20	Small-molecule inhibitors of dimeric transcription factors: Antagonism of proteinâ€“protein and proteinâ€“DNA interactions. MedChemComm, 2012, 3, 541.	3.4	27
21	Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer. Theranostics, 2020, 10, 7510-7526.	10.0	27
22	Structural Reâ€engineering of the Î±â€Helix Mimetic JYâ€1â€106 into Small Molecules: Disruption of the Mclâ€1â€“Bakâ€BH3 Proteinâ€“Protein Interaction with 2,6â€Diâ€Substituted Nicotinates. ChemMedChem, 2016, 11, 827-833.	3.1	25
23	Chromatography-Free Entry to Substituted Salicylonitriles: Mitsunobu-Triggered Domino Reactions of Salicylaldoximes. Journal of Organic Chemistry, 2015, 80, 1229-1234.	3.2	22
24	Azodicarbonyl dimorpholide (ADDM): an effective, versatile, and water-soluble Mitsunobu reagent. Tetrahedron Letters, 2013, 54, 4624-4628.	1.4	20
25	Regioselective alkylation of the exocyclic nitrogen of adenine and adenosine by the Mitsunobu reaction. Tetrahedron Letters, 2010, 51, 2948-2950.	1.4	19
26	VLA4-Targeted Nanoparticles Hijack Cell Adhesionâ€“Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival. Clinical Cancer Research, 2021, 27, 1974-1986.	7.0	17
27	A quantitative, surface plasmon resonance-based approach to evaluating DNA binding by the c-Myc oncoprotein and its disruption by small molecule inhibitors. Journal of Biological Methods, 2015, 2, e18.	0.6	17
28	Recapitulating the Î±-helix: nonpeptidic, low-molecular-weight ligands for the modulation of helix-mediated proteinâ€“protein interactions. Future Medicinal Chemistry, 2013, 5, 2157-2174.	2.3	16
29	CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model. Biochemical and Biophysical Research Communications, 2017, 484, 262-268.	2.1	16
30	Discovery of Mcl-1 inhibitors based on a thiazolidine-2,4-dione scaffold. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 523-528.	2.2	14
31	Multi-Facial, Non-Peptidic Î±-Helix Mimetics. Biology, 2015, 4, 540-555.	2.8	13
32	KrÃ¶hnke pyridines: Rapid and facile access to Mcl-1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1949-1953.	2.2	13
33	Baeyerâ€“Villiger rearrangement of a substituted pyrrole by Oxone. Tetrahedron Letters, 2014, 55, 3111-3113.	1.4	12
34	Discovery and lead identification of quinazoline-based BRD4 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3483-3488.	2.2	12
35	Fine-tuning the chemo- and regioselective alkylation of 1,4-benzodiazepines: further applications of the Mitsunobu reaction. MedChemComm, 2012, 3, 1160.	3.4	11
36	BCL-xL/MCL-1 inhibition and RARÎ³ antagonism work cooperatively in human HL60 leukemia cells. Experimental Cell Research, 2014, 327, 183-191.	2.6	10

#	Article	IF	Citations
37	Construction of 1H-indazoles from ortho-aminobenzoximes by the Mitsunobu reaction. Tetrahedron Letters, 2019, 60, 150929.	1.4	10
38	O-Alkylation of 3-hydroxyisoxazoles predominates under Mitsunobu conditions. Tetrahedron Letters, 2014, 55, 1693-1696.	1.4	9
39	Synthesis, characterization and antineoplastic activity of bis-aziridinyl dimeric naphthoquinone â€“ A novel class of compounds with potent activity against acute myeloid leukemia cells. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 6-10.	2.2	9
40	Orthogonal targeting of osteoclasts and myeloma cells for radionuclide stimulated dynamic therapy induces multidimensional cell death pathways. Theranostics, 2021, 11, 7735-7754.	10.0	8
41	Denaturation and accelerated proteolysis of sizeable heme proteins by synthetic metalloporphyrins. New Journal of Chemistry, 2007, 31, 623.	2.8	7
42	Structure–activity exploration of a small-molecule Lipid II inhibitor. Drug Design, Development and Therapy, 2015, 9, 2383.	4.3	7
43	Therapeutic potential of Bcl-xl/Mcl-1 synthetic inhibitor JY-1-106 and retinoids for human triple-negative breast cancer treatment. Oncology Letters, 2018, 15, 7231-7236.	1.8	7
44	Towards Development of Small Molecule Lipid II Inhibitors as Novel Antibiotics. PLoS ONE, 2016, 11, e0164515.	2.5	7
45	Recent applications of covalent chemistries in proteinâ€“protein interaction inhibitors. RSC Medicinal Chemistry, 2022, 13, 921-928.	3.9	7
46	Rationally Designed Polypharmacology: Î±â€Helix Mimetics as Dual Inhibitors of the Oncoproteins Mclâ€1â€‰and HDM2. ChemMedChem, 2020, 15, 1691-1698.	3.2	6
47	Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6. RSC Medicinal Chemistry, 2021, 12, 178-196.	3.9	6
48	CG223, a novel BET inhibitor, exerts TGF-Î²1-mediated antifibrotic effects in a murine model of bleomycin-induced pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2021, 70, 102057.	2.6	6
49	Mechanistic Analysis of an Extracellular Signalâ€“Regulated Kinase 2â€“Interacting Compound that Inhibits Mutant BRAF-Expressing Melanoma Cells by Inducing Oxidative Stress. Journal of Pharmacology and Experimental Therapeutics, 2021, 376, 84-97.	2.5	5
50	Synthetic, structural mimetics of the Î²-hairpin flap of HIV-1 protease inhibit enzyme function. Bioorganic and Medicinal Chemistry, 2015, 23, 7095-7109.	3.0	4
51	Chromatography-free, Mitsunobu-triggered heterocyclizations of salicylhydroxamic acids to 3-hydroxybenzisoxazoles. Tetrahedron Letters, 2016, 57, 5301-5303.	1.4	4
52	3JC48-3 (methyl 4â€²-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1â€²-biphenyl]-3-carboxylate): a novel MYC/MAX dimerization inhibitor reduces prostate cancer growth. Cancer Gene Therapy, 2022, 29, 1550-1557.	4.6	4
53	Scaffold hopping from indoles to indazoles yields dual MCL-1/BCL-2 inhibitors from MCL-1 selective leads. RSC Medicinal Chemistry, 2022, 13, 963-969.	3.9	4
54	Optimization of a small-molecule Lipid II binder. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1849-1853.	2.2	2

#	Article	IF	Citations
55	The ERK2 DBP domain opposes pathogenesis of a JAK2V617F-driven myeloproliferative neoplasm. Blood, 2022, , .	1.4	1
56	Novel Bromodomain Inhibitors Suppress Proliferation of Multiple Myeloma Cells. Blood, 2015, 126, 4432-4432.	1.4	0
57	A Novel BRD4 Inhibitor CA2 Suppresses MM Cell Proliferation in an Orthotopic Myeloma Mouse Model. Blood, 2016, 128, 4722-4722.	1.4	0